Dipraglurant
 | |
| Clinical data | |
|---|---|
| ATC code | None |
| Identifiers | |
| |
| CAS Number | 872363-17-2 |
| PubChem (CID) | 44557636 |
| ChemSpider | 25069676 |
| Chemical and physical data | |
| Formula | C16H12FN3 |
| Molar mass | 265.285 g/mol |
| 3D model (Jmol) | Interactive image |
| |
| |
Dipraglurant (INN) (code name ADX-48621) is a negative allosteric modulator of the mGlu5 receptor which is under development by Addex Therapeutics for the treatment of Parkinson's disease levodopa-induced dyskinesia (PD-LID).[1][2][3] As of 2014, it is in phase II clinical trials for this indication.[1] Addex Therapeutics is also investigating an extended-release formulation of dipraglurant for the treatment of non-parkinsonian dystonia.[4]
See also
References
- 1 2 Ana Martinez; Carmen Gil (29 July 2013). Emerging Drugs and Targets for Parkinson's Disease. Royal Society of Chemistry. pp. 255–. ISBN 978-1-84973-617-6.
- ↑ John E. Macor (2012). Annual Reports in Medicinal Chemistry. Academic Press. pp. 83–. ISBN 978-0-12-396492-2.
- ↑ Susan H. Fox; Jonathan M. Brotchie (8 October 2014). Levodopa-Induced Dyskinesia in Parkinson's Disease. Springer. pp. 323–. ISBN 978-1-4471-6503-3.
- ↑ Addex Therapeutics. "Dipraglurant-ER for dystonia".
External links
- Dipraglurant-IR for Parkinson's disease levodopa-induced dyskinesia - Addex Therapeutics
- Dipraglurant-ER for dystonia - Addex Therapeutics
This article is issued from Wikipedia - version of the 4/2/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.